Roche chucks out phase 3 ipatasertib combo tests, midstage IL-33 asthma, BTKi arthritis trials in Q4 clear-out

Swiss major Roche is dumping a series of cancer, autoimmune and respiratory drugs in mid- to late-stage tests.

In its fourth-quarter and full-year results published (PDF) early Thursday morning, Roche said it had “removed from phase 3” two breast cancer combos using its Akt inhibitor ipatasertib (aka RG7440), as pressure on the asset after an ESMO failure last year.